The β-fibrinogen –455G/A gene polymorphism and the risk of ischaemic stroke in a Polish population

Golenia, Aleksandra; Chrzanowska-Wasko, Joanna; Jagiełła, Jeremiasz; Wnuk, Marcin; Ferens, Antoni; Klimkowicz‐Mrowiec, Aleksandra; Adamski, Mateusz; Ciećko-Michalska, Irena; Słowik, Agnieszka

doi:10.5114/ninp.2013.34462

Cited by 9 publications

(5 citation statements)

References 10 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a similar study in Poland, 426 ischemic stroke patients and 234 controls were examined. Genotype frequencies were GG 75%, GA 36.8%, AA 6.6% in patient group and GG 5.3%, GA 32.9% and AA 9.8% in control group, and no significant difference was found between the patient and control groups in terms of this mutation [44]. GA genotype frequency, which is 33.3% in our patient group, is similar to the genotype frequency in the study conducted in Poland.…”

Section: β-Fibrinojen -455g > a Mutationsupporting

confidence: 82%

Analysis of Twelve Cardiovascular Disease Related Gene Mutations among Turkish Patients with Coronary Artery Disease

Durmuş¹,

Nevin²,

Yuksel³

et al. 2020

Int J Blood Res Disord

View full text Add to dashboard Cite

Background: Coronary artery disease (CAD) is a multifactorial disorder. It is important to identify gene mutations that may be responsible for the development of CAD. The aim of this study was to determine the frequency of twelve cardiovascular disease (CVD) related gene mutations in coronary artery patients. Methods:The CVD StripAssay (Vienna Lab, Austria) was performed to analyze the twelve gene mutations on 52 coronary artery patients and 39 healthy controls. After DNA isolation from blood samples, hybridization with biotin marked probes was performed to PCR products containing the related region of mutant genes. Chisquare tests were used for statistical analyses.Results: Any differences were not observed between coronary artery patients and healthy controls in terms of the frequencies of studied twelve gene mutations except MTHFR A1298C mutation. It was observed that heterozygous and homozygous mutant genotypes of MTHFR A1298C mutation have protective effects against coronary artery disease [p = 0.06, in 95% CI OR = 0.205 (0.0421-1.001)]. Although all the three genotypes of PAI-1 4G/5G, ACE I/D and MTHFR C677T mutations were observed in both groups; homozygous mutant genotypes weren't observed for the Factor V Leiden, Factor V H1299R, Prothrombin G20210A, Factor XIII V34L, β-Fibrinojen -455G > A, HPA-1 1a/1b mutations in any of the groups. Heterozygote and homozygote mutant genotypes of APOB R3500Q mutation was not seen in both groups. When the patient group was evaluated in terms of compound genotypes, the rate of two mutations (ACE I/D, MTHFR A1298C) was 56%, the rate of three mutations (PAI-1 4G/5G, MTHFR A1298C, ACE I/D) was 53%, the rate of four mutations (PAI-1 4G/5G, MTHFR A1298C, HPA-1 1a/1b, ACE I/D) was 33%. High cholesterol, the number of clogged arteries and smoking rates was high in CAD patients with compound genotypes or carrying mutations in multiple genes compared the others. Conclusion:Among 12 studied gene mutations, only the MTH-FR A1298C mutation was determined to have a protective effect against CAD. In addition, cumulative effects of the mutant genotypes and environmental factors on people with the combined genotypes may be trigger for CAD.

show abstract

Section: β-Fibrinojen -455g > a Mutationsupporting

confidence: 82%

Analysis of Twelve Cardiovascular Disease Related Gene Mutations among Turkish Patients with Coronary Artery Disease

Durmuş¹,

Nevin²,

Yuksel³

et al. 2020

Int J Blood Res Disord

View full text Add to dashboard Cite

show abstract

“…Moreover, it was found that -455 G/A was independently associated with an increased risk of CES in AF patients and the significance remained after the Bonferroni correction in the additive (AA vs. GA vs. GG), dominant (AA + GA vs. GG), and recessive models (AA vs. GA + GG), with ORs of 1.548 (95% CI: 1.251–1.915, p = 0.001), 1.588 (95% CI: (1.226–2.057, p = 0.003), and 2.394 (95% CI: 1.357–4.223, p = 0.015) [ 89 ]. In the study by Golenia et al, which included 426 Polish patients with ischemic stroke, it was shown that the β-fibrinogen -455 G/A gene polymorphism was not a risk factor for this disease [ 90 ]. Reviewing the results of other studies, one can find evidence of a different effect of the presence of the -455 G/A polymorphism on the risk of CAD (increased risk, no effect and protective effect) [ 91 , 92 , 93 ].…”

Section: Fibrinogen Molecular Modifications and Cardiovascular Riskmentioning

confidence: 99%

Fibrinogen and Atherosclerotic Cardiovascular Diseases—Review of the Literature and Clinical Studies

Surma

Banach

2021

IJMS

View full text Add to dashboard Cite

Atherosclerotic cardiovascular diseases (ASCVD), including coronary artery disease, cerebrovascular disease, and peripheral arterial disease, represent a significant cause of premature death worldwide. Biomarkers, the evaluation of which would allow the detection of ASCVD at the earliest stage of development, are intensively sought. Moreover, from a clinical point of view, a valuable biomarker should also enable the assessment of the patient’s prognosis. It has been known for many years that the concentration of fibrinogen in plasma increases, inter alia, in patients with ASCVD. On the one hand, an increased plasma fibrinogen concentration may be the cause of the development of atherosclerotic lesions (increased risk of atherothrombosis); on the other hand, it may be a biomarker of ASCVD, as it is an acute phase protein. In addition, a number of genetic polymorphisms and post-translational modifications of fibrinogen were demonstrated that may contribute to the risk of ASCVD. This review summarizes the current data on the importance of fibrinogen as a biomarker of ASCVD, and also presents the relationship between molecular modifications of this protein in the context of ASCVD.

show abstract

“…A positive association with hypertension and smoking was previously reported by Martiskainen et al (12) in lacunar stroke patients carriers of the FGB −455G>A A allele. In contrast, other studies (30,31) failed to find any association between the FGB −455G>A polymorphism and smoking or hypertension in patients with stroke. Following the available literature data on the association of GP IIIa PIA1/A2 polymorphism with hypertension and smoking, we found conflicting results.…”

Section: Discussionmentioning

confidence: 65%

FGB -455 G>A and GP IIIa PIA1/A2 polymorphisms in a group of Romanian stroke patients

Petrisor

Cătană

Mărginean

et al. 2016

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

Introduction: Being a multifactorial disease, stroke is one of a major causes of death and disability worldwide. Several genetic polymorphisms have been associated with stroke etiophatology and FGB −455 G>A and GP IIIa PIA1/A2 are among them. In the present study, we investigated the association between FGB −455 G>A and GP IIIa PIA1A2 polymorphisms and the risk of ischemic stroke in a group of Romanian stroke patients. Subjects and methods: This case-control study included 148 patients with ischemic stroke and 150 healthy age, sex and ethnically matched unrelated controls. FGB −455G>A and GP IIIa PIA1A2 genotyping was carried out using PCR-RFLP. The association of FGB −455G>A and GP IIIa PIA1A2 polymorphisms and cardiovascular risk factors with ischemic stroke was tested using logistic regression analysis. Results: Molecular analysis did not reveal an increased frequency of the FGB -455 G>A variant allele and GP IIIa PIA1/A2 variant allele in the study group compared to the control group (p = 0.140, OR = 0.750, 95% CI = 0.522 - 1.077; p = 0.823, OR = 0.944, 95% CI = 0.558 - 1.599 respectively). Furthermore, after performing logistic regression analysis adjusted for the known risk factors, a positive association with stroke was found in smokers (p = 0.026, OR = 1.800, 95% CI = 1.071 - 3.024) Conclusions: No association was found between FGB −455 G>A and GP IIIa PIA1/A2 polymorphisms and ischemic stroke in the studied population.

show abstract

The β-fibrinogen –455G/A gene polymorphism and the risk of ischaemic stroke in a Polish population

Abstract: The β-fibrinogen -455G/A gene polymorphism is not a risk factor for ischaemic stroke in a Polish population.

Cited by 9 publications

References 10 publications

Analysis of Twelve Cardiovascular Disease Related Gene Mutations among Turkish Patients with Coronary Artery Disease

Analysis of Twelve Cardiovascular Disease Related Gene Mutations among Turkish Patients with Coronary Artery Disease

Fibrinogen and Atherosclerotic Cardiovascular Diseases—Review of the Literature and Clinical Studies

FGB -455 G>A and GP IIIa PIA1/A2 polymorphisms in a group of Romanian stroke patients

Contact Info

Product

Resources

About